NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection

Bibliography

• WHO. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board. J Viral Hepat 1999;6(1):35-47
   PubMedGoogle Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-16
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364(25):2417-28
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014-24
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207-17
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65
   PubMed Web of Science ®Google Scholar
• Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004;85(Pt 9):2485-502
   PubMedGoogle Scholar
• Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012;32(Suppl 1):88-102
   PubMed Web of Science ®Google Scholar
• Schmitz U, Tan SL. NS5A-from obscurity to new target for HCV therapy. Recent Pat Antiinfect Drug Discov 2008;3(2):77-92
   PubMedGoogle Scholar
• Fridell RA, Qiu D, Valera L, et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011;85(14):7312-20
   PubMed Web of Science ®Google Scholar
• Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465(7294):96-100
   PubMed Web of Science ®Google Scholar
• Lemm JA, O'Boyle D II, Liu M, et al. Identification of hepatitis C virus NS5A inhibitors. J Virol 2010;84(1):482-91
   PubMed Web of Science ®Google Scholar
• Lee C, Ma H, Hang JQ, et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 2011;414(1):10-18
   PubMed Web of Science ®Google Scholar
• Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 2013;110(10):3991-6
   PubMed Web of Science ®Google Scholar
• Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010;54(9):3641-50
   PubMed Web of Science ®Google Scholar
• Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011;54(6):1924-35
   PubMed Web of Science ®Google Scholar
• Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011;54(6):1956-65
   PubMed Web of Science ®Google Scholar
• Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012;12(9):671-7
   PubMed Web of Science ®Google Scholar
• Izumi N, Asahina Y, Yokosuka O, et al. Combination Therapy Of Treatment-Naive And Nonresponder Patients With Hcv Genotype 1 Infection With Daclatasvir (Dcv; Bms-790052), An NS5A Replication Complex Inhibitor, in Combination With Peginterferon Alfa-2a and Ribavirin. [Abstract PP13-004]. Hepatol Int 2012;6(1):162
   Google Scholar
• Lok A, Gardiner D, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366(3):216-24
   PubMed Web of Science ®Google Scholar
• Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55(3):742-8
   PubMed Web of Science ®Google Scholar
• Lok A, Gardiner D, Hezode C, et al. Sustained Virologic Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor) With or Without Peginterferon Alfa-2a/Ribavirin (PEG/RBV) [abstract 1985]. 2013 Annual Meeting of the APASL; 6–10 June 2013; Singapore
   Google Scholar
• Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Sustained Virologic Response with Daclatasvir (NS5A inhibitor) Plus Sofosbuvir (nucleotide NS5B inhibitor) +/2 Ribavirin for HCV enotypes 1-3 [Abstract 1263]. Hepatol Int 2013;7(Suppl 1):389-90
   Google Scholar
• Everson G, Sims K, Rodriguez-Torres M, et al. Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients. [Abstract 1423]. J Hepatol 2013;58(Suppl 1):S573
   Web of Science ®Google Scholar
• Dore G, Lawitz E, Hézode C, et al. Daclatasvir combined with peginterferon alfa 2a alfa-and ribavirin for 12 or 16 weeks in patients with hepatitis c virus genotype 2 or 3 infection: command Gt 2/3 study [abstract 1418]. J Hepatol 2013;58(Suppl 1):S570
   Google Scholar
• Hezode C, Hirschfield G, Ghesquiere W, et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive hcv-genotype 1 or 4 patients: phase 2b COMMAND-1 SVR12 results [abstract 755]. Hepatology 2012;56(Suppl 1):553A
   Google Scholar
• Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58(4):655-62
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Sustained Virologic Response with Daclatasvir (NS5A inhibitor) Plus Sofosbuvir (nucleotide NS5B inhibitor) +/2 Ribavirin for HCV enotypes 1-3 [Abstract 1263]. 2013 Annual Meeting of the APASL; 6–10 June 2013; Singapore
   Google Scholar
• Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) [abstract 1417]. J Hepatol 2013;58(Suppl 1):S570
   Google Scholar
• Jacobson I, Dimitrova D, Hughes E, et al. Safety profile of daclatasvir in combination with peginterferon alfa and ribavirin in 1100 patients with chronic HCV infection treated in phase 2 studies [abstract 1203]. J Hepatol 2013;58(Suppl 1):S489
   Google Scholar
• Bifano M, Connolly S, Hwang C, et al. The effect of coadministration of the proton-pump inhibitor omeprazole on the pharmacokinetics of daclatasvir in healthy subjects [abstract 794]. J Hepatol 2013;58(Suppl 1):S324
   Google Scholar
• Trials of daclatasvir with VX-135 and TMC-435 have been registered at ClinicalTrials.gov with the indentifiers NCT01842451 and NCT01628692, respectively. Treatment with MK-5172 and daclatasvir has not yet been registered at ClinicalTrials.gov.
   Google Scholar